Concert Pharmaceuticals, Inc. (CNCE)
(Delayed Data from NSDQ)
$10.65 USD
+0.69 (6.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.67 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.65 USD
+0.69 (6.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.67 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.
Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) stock rallies on consistent expansion in patient population through label expansions of Kalydeco and Orkambi and positive data readout from pivotal studies.
Concert Pharmaceuticals Plunges on Patent Petition Setback
by Zacks Equity Research
Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.
Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) saw its shares rise nearly 6% on the day.
Vertex Gets CHMP Recommendation for Orkambi Label Expansion
by Zacks Equity Research
Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.
Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media
by Zacks Equity Research
Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media
5 Stocks to Bet on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated's (VRTX) Q2 results were encouraging, as it topped earnings and revenues expectations backed by higher sales of both its CF drugs.
Here's Why Investors Are Glued to Vertex Pharma (VRTX) Stock
by Zacks Equity Research
Vertex Pharmaceuticals, Inc. (VRTX), has been attracting investor attention.
Concert Pharma Falls After Clinical Hold on Hair Loss Drug
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.
Why Is Vertex Pharma (VRTX) Stock Soaring This Year?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc.'s (VRTX) shares have risen 57.8% this year so far, outperforming the increase of 1.3% for the Zacks classified Large-Cap Pharma industry.
Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.
Will Concert Pharmaceuticals (CNCE) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Concert Pharmaceuticals Inc (CNCE).
Moving Average Crossover Alert: Concert Pharmaceuticals (CNCE)
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
After Valeant, Here are 5 Drug Stocks Bill Ackman Should Buy Instead
by Arpita Dutt
With Bill Ackman finally deciding to exit Valeant (VRX), here is a look at 5 Zacks Rank #1 and #2 drug stocks that the billionaire investor could consider buying.
Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.
Concert's (CNCE) CTP-656 Gets Orphan Drug Status in U.S.
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) announced that the FDA has granted orphan drug designation to its candidate CTP-656 for the treatment of cystic fibrosis.
Concert Offers Update on Cystic Fibrosis Drug, Stock Down
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe.
Will Concert Pharmaceuticals (CNCE) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Concert Pharmaceuticals Inc (CNCE)